Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Anne J Huiberts; Brechje de Gier; Christina E Hoeve; Hester E de Melker; Susan Jm Hahné; Gerco den Hartog; Janneke Hhm van de Wijgert; Susan van den Hof; Mirjam J Knol

doi:10.2807/1560-7917.ES.2023.28.7.2300087

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Euro Surveill. 2023 Feb;28(7):2300087. doi: 10.2807/1560-7917.ES.2023.28.7.2300087.

Authors

Affiliations

¹ Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
² Radboud Centre for Infectious Diseases, Radboudumc, Nijmegen, the Netherlands.
³ Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht (UMCU), Utrecht, the Netherlands.

PMID: 36795500
PMCID: PMC9936593
DOI: 10.2807/1560-7917.ES.2023.28.7.2300087

Abstract

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

Keywords: COVID-19; SARS-CoV-2; vaccine effectiveness.

MeSH terms

COVID-19* / prevention & control
Humans
Netherlands / epidemiology
Prospective Studies
RNA, Messenger
SARS-CoV-2 / genetics
Vaccination

Substances

RNA, Messenger